Australia vs Kazakhstan: Treatment success rate for patients treated for MDR-TB
Australia
84.0%
in 2022
Kazakhstan
84.0%
in 2022
Australia rank
38th
Kazakhstan rank
38th
Treatment success rate for patients treated for MDR-TB over time
- Australia
- Kazakhstan
How they compare
Australia currently reports 84.0% against 84.0% in Kazakhstan, a difference of 0.0%.
The two have swapped places 4 times across 16 shared years of data; in 2006 it was Kazakhstan ahead.
Australia ranks 38th and Kazakhstan ranks 38th of 163 countries.
Kazakhstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Australia | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 72.7% | 76.0% | 3.3% | Kazakhstan |
| 2010s | 73.4% | 76.4% | 3.0% | Kazakhstan |
| 2020s | 75.7% | 80.7% | 5.0% | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Australia or Kazakhstan?
- Australia, at 84.0% against 84.0% in Kazakhstan as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Australia and Kazakhstan?
- 0.0%, with Australia ahead.
- How many years of comparable data are there for Australia and Kazakhstan?
- 16 years are reported by both, from 2006 to 2022.
- How do Australia and Kazakhstan rank globally for treatment success rate for patients treated for mdr-tb?
- Australia ranks 38th and Kazakhstan ranks 38th of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.